nimodipine has been researched along with Intraocular Pressure in 6 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
Intraocular Pressure: The pressure of the fluids in the eye.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Preparation and evaluation of topical ophthalmic formulations containing nimodipine-CD complexes prepared using HP-β-CD, SBE-β-CD and M-β-CD for the management of glaucoma." | 7.85 | Nimodipine Ophthalmic Formulations for Management of Glaucoma. ( Abd-Elgawad, AH; El-Dahan, MS; Jablonski, MM; Maria, DN; Soliman, OA, 2017) |
| "Preparation and evaluation of topical ophthalmic formulations containing nimodipine-CD complexes prepared using HP-β-CD, SBE-β-CD and M-β-CD for the management of glaucoma." | 3.85 | Nimodipine Ophthalmic Formulations for Management of Glaucoma. ( Abd-Elgawad, AH; El-Dahan, MS; Jablonski, MM; Maria, DN; Soliman, OA, 2017) |
| " In a placebo-controlled fashion, nimodipine was orally administered at a dosage of 30 mg three times a day for two periods of 5 days including a 9-day washout interval." | 2.72 | Nimodipine plasma concentration and retinal blood flow in healthy subjects. ( Geisslinger, G; Leidig, S; Lötsch, J; Michelson, G; Wärntges, S, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maria, DN | 1 |
| Abd-Elgawad, AH | 1 |
| Soliman, OA | 1 |
| El-Dahan, MS | 1 |
| Jablonski, MM | 1 |
| Michalk, F | 1 |
| Michelson, G | 2 |
| Harazny, J | 1 |
| Werner, U | 1 |
| Daniel, WG | 1 |
| Werner, D | 1 |
| Wärntges, S | 1 |
| Leidig, S | 1 |
| Lötsch, J | 1 |
| Geisslinger, G | 1 |
| Bose, S | 2 |
| Piltz, JR | 2 |
| Breton, ME | 1 |
| Cioffi, GA | 1 |
| Lanchoney, D | 1 |
3 trials available for nimodipine and Intraocular Pressure
| Article | Year |
|---|---|
Nimodipine plasma concentration and retinal blood flow in healthy subjects.
Topics: Administration, Oral; Adult; Blood Flow Velocity; Blood Pressure; Calcium Channel Blockers; Chromato | 2006 |
Nimodipine, a centrally active calcium antagonist, exerts a beneficial effect on contrast sensitivity in patients with normal-tension glaucoma and in control subjects.
Topics: Aged; Blood Pressure; Calcium Channel Blockers; Contrast Sensitivity; Cross-Over Studies; Double-Bli | 1995 |
The effect of nimodipine, a centrally active calcium antagonist, on visual function and mascular blood flow in patients with normal-tension glaucoma and control subjects.
Topics: Aged; Blood Flow Velocity; Blood Pressure; Calcium Channel Blockers; Color Perception; Cross-Over St | 1998 |
3 other studies available for nimodipine and Intraocular Pressure
| Article | Year |
|---|---|
Nimodipine Ophthalmic Formulations for Management of Glaucoma.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Administration, Ophthalmic; Animals; beta-Cyclodextrins; Chemistr | 2017 |
Single-dose nimodipine normalizes impaired retinal circulation in normal tension glaucoma.
Topics: Blood Circulation; Blood Flow Velocity; Blood Pressure; Calcium Channel Blockers; Female; Glaucoma, | 2004 |
Three assumptions: ocular blood flow and glaucoma.
Topics: Blood Flow Velocity; Calcium Channel Blockers; Ciliary Arteries; Color Perception; Glaucoma, Open-An | 1998 |